Your trusted destination for CME, CPD & Medical Education across the Middle East.
BlueDot
Dr. Kamran Khan is a Canadian infectious disease physician, epidemiologist, professor, and biotechnology entrepreneur internationally recognized for his contributions to global infectious disease surveillance, epidemic intelligence, and public health innovation. His work combines clinical medicine, epidemiological research, big data, and artificial intelligence to improve the detection and monitoring of emerging infectious disease threats.
He completed his medical education and postgraduate training at the University of Toronto, followed by specialized training in internal medicine, infectious diseases, preventive medicine, and public health. His professional interests developed around the relationship between human mobility, international travel, and the spread of infectious diseases.
A defining moment in his career was the 2003 SARS outbreak in Toronto, during which he witnessed the significant impact of an emerging infectious disease on healthcare workers, hospitals, and communities. This experience inspired him to investigate how technology and epidemiological modelling could help identify outbreaks earlier and improve public health preparedness.
Dr. Khan became a clinician-scientist at St. Michael's Hospital in Toronto and a Professor of Medicine and Public Health at the University of Toronto. His research examines how globalization, migration, international air travel, and population movement influence the emergence and international spread of infectious diseases. His scientific work has appeared in leading journals, including The New England Journal of Medicine, The Lancet, Science, and Nature.
In 2013, he founded BlueDot, a digital health and infectious disease intelligence company that combines artificial intelligence, epidemiology, and human expertise to detect and monitor infectious disease threats. The company's technology analyzes large volumes of information, including news reports, health data, population movement, and airline travel patterns, to identify potential outbreaks and assess their possible international spread.
BlueDot gained international attention during the early stages of the COVID-19 pandemic for identifying signals of an unusual pneumonia outbreak in Wuhan, China, and assessing the potential for international transmission. Through his leadership, Dr. Khan has helped advance the use of technology in epidemic preparedness and global health security.
He has also contributed to international public health discussions and advisory initiatives, including work connected with the World Health Organization and the United States government. In 2025, he was elected a Fellow of the Canadian Academy of Health Sciences, recognizing his contributions to health research and innovation.

dmg events
dmg events